Drug intelligence / Profile preview

Qualia Senolytic

Development stage
Unknown
Lead developer
Neurohacker Collective
Modality
Small Molecules
Administration
Oral
01

Overview

Qualia Senolytic is a multi-ingredient dietary supplement developed by Neurohacker Collective designed to support cellular health by targeting senescent cells, often referred to as "zombie cells." The formulation is a complex blend of polyphenols and botanical extracts, including fisetin, quercetin (as Quercefit phytosome), luteolin, curcumin (as HydroCurc), milk thistle (silymarin), piperlongumine (from *Piper longum*), and olive leaf extract. It is typically administered in a "pulsed" dosing regimen, such as two days per month, to promote the selective clearance of senescent cells that accumulate with age and contribute to the Senescence-Associated Secretory Phenotype (SASP), which is characterized by the release of pro-inflammatory cytokines. Clinical research, including pilot studies like NCT06953518, evaluates its efficacy in attenuating systemic inflammatory markers such as TNF-alpha, IL-1 beta, and IL-8, as well as its impact on aging-related health indicators like frailty and physical function.

Brand names
Qualia Senolytic
02

Targets

TNFA (Tumor necrosis factor alpha (soluble))BCL2L1 (B-cell lymphoma-extra large protein)IL-6 (Interleukin 6)

Beyond the preview

Go deeper on Qualia Senolytic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qualia Senolytic.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call